PLoS ONE · 2014 · 57 citations · 45 references
Life SciencesImmunologyMaterials ScienceImmunizationNanomaterialsVaccinologyNanoparticle FormulationsVaccine DeliveryVaccine FormulationViral VaccinesVirus-like NanoparticlesVirus-like Particle VaccinesB Cell Response InductionDynamic Light ScatteringNanoparticle Vaccine FormulationsNanoparticlesRecombinant Virus-like ParticlesSilicon DioxideViral-like Particle VaccinesVirus-like Particles
Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10-20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund's adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40% of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBc-derived virus-like particles as the biological component.
45
Barbara Rehermann, Carlo Ferrari, C Pasquinelli et al. · Nature Medicine · 1996 · 849 citations
Sandro Giannini, Emmanuel Hanon, Philippe Moris et al. · Vaccine · 2006 · 498 citations
Mario U. Mondelli, G Vergani, A. Albertí et al. · The Journal of Immunology · 1982 · 393 citations · Full text